Skip to main content
Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
83.81
-2.93 (-3.38%)
At close: Apr 28, 2026, 4:00 PM EDT
84.58
+0.77 (0.92%)
Pre-market: Apr 29, 2026, 7:21 AM EDT

Nektar Therapeutics Revenue

In the year 2025, Nektar Therapeutics had annual revenue of $55.23M, down -43.89%. Nektar Therapeutics had revenue of $21.81M in the quarter ending December 31, 2025, a decrease of -25.25%.

Revenue (ttm)
$55.23M
Revenue Growth
-43.89%
P/S Ratio
51.20
Revenue / Employee
$876,698
Employees
63
Market Cap
2.83B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202555.23M-43.20M-43.89%
Dec 31, 202498.43M8.31M9.22%
Dec 31, 202390.12M-1.93M-2.10%
Dec 31, 202292.06M-9.85M-9.67%
Dec 31, 2021101.91M-51.01M-33.36%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Tarsus Pharmaceuticals 451.36M
Arcutis Biotherapeutics 376.07M
Soleno Therapeutics 190.41M
Beam Therapeutics 139.74M
Alumis 24.05M
Immunome 6.94M
Celldex Therapeutics 1.55M
Revenue Rankings

NKTR News

More News